One potential oncolytic adenovirus expressing Lipocalin-2 for colorectal cancer therapy

Area of Science:

• Oncology
• Virology
• Gene Therapy

Background:

• Colorectal cancer presents a significant global health challenge due to its aggressive nature and high mortality rate.
• Current therapeutic options for colorectal cancer are limited, necessitating the development of novel treatment strategies.
• Cancer-targeting gene-virotherapy (CTGVT) emerges as a promising approach for effective cancer treatment.

Purpose of the Study:

• To evaluate the antitumor efficacy of ZD55-Lipocalin-2, an oncolytic adenovirus engineered to express Lipocalin-2, in colorectal cancer models.
• To investigate the mechanisms underlying the therapeutic effects of ZD55-Lipocalin-2, including its impact on tumor cell viability and apoptosis.

Main Methods:

• ZD55-Lipocalin-2 was constructed by modifying an oncolytic adenovirus (deleting E1B55-KD) and incorporating the Lipocalin-2 gene.
• In vitro studies assessed the cytopathic effects and cell growth inhibition induced by ZD55-Lipocalin-2.
• In vivo experiments utilized a human colorectal cancer xenograft model in nude mice to examine antitumor activity.

Main Results:

• ZD55-Lipocalin-2 demonstrated significant inhibition of colorectal cancer growth through selective cytolysis and induction of apoptosis.
• The treatment led to a reduction in tumor microvessel density, suggesting an anti-angiogenic effect.
• The combined gene-virotherapy (ZD55-Lipocalin-2) exhibited superior anticancer potential compared to monotherapies using either Lipocalin-2 gene therapy or the ZD55 oncolytic adenovirus alone.

Conclusions:

• ZD55-Lipocalin-2 exhibits potent antitumor activity against colorectal cancer, surpassing that of individual therapeutic components.
• This novel CTGVT strategy holds significant promise as a potential therapeutic agent for colorectal cancer treatment.
• Further investigation into ZD55-Lipocalin-2 could pave the way for innovative clinical applications in oncology.